Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

2022299 citationsJournal Articlehybrid Open Access

Authors

Lin Shen · Peking University

Ken Kato · National Cancer Center Hospital East

Sung‐Bae Kim · Ulsan College

Jaffer A. Ajani · The University of Texas MD Anderson Cancer Center

Kuaile Zhao · Fudan University Shanghai Cancer Center

Zhiyong He · Fujian Medical University

Xinmin Yu ·

Abstract

Tislelizumab significantly improved OS compared with chemotherapy as second-line therapy in patients with advanced or metastatic ESCC, with a tolerable safety profile. Patients with programmed death-ligand 1 TAP ≥ 10% also demonstrated statistically significant survival benefit with tislelizumab versus chemotherapy.

Topics & Keywords

Esophageal Cancer Research and Treatment Cancer Immunotherapy and Biomarkers Pancreatic and Hepatic Oncology Research

Publication Details

Published in: Journal of Clinical Oncology

Volume 40, Issue 26, pp. 3065-3076

DOI: 10.1200/jco.21.01926

Field-Weighted Citation Impact: 61.24

Command Palette

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Authors

Abstract

Topics & Keywords

Publication Details